Gilead gains rights to Compugen’s immunotherapy programme in deal worth up to $848m

2023-12-20
·
交易
PMLiVE
引进/卖出免疫疗法
Gilead Sciences has announced an agreement with Compugen worth up to $848m to exclusively licence its preclinical antibody programme against IL-18 binding protein.
Gilead Sciencesnotherapy company utilises its prCompugen computational discovery capabilities to identify new drug targets and biological patIL-18 binding proteinnovel cancer immunotherapies.
The cancermme includes COM503, a high affinity antibody that blocks the interaction between IL-18 binding protein and IL-18, releasing natural IL-18 in the tumour microcancernment and inhibiting cancer growth.
“IL-18 is one of the raCOM503okines which is naturally inhibited by an endogenous binding prIL-18 binding proteinniqueIL-18rtunity to use a bloIL-18 antibodtumourncrease the local concentrations cancer18 within the tumour where it can potentiate anti-tumour immune responses, thereby potentially overcoming the limitations of systemically administered cytokines,” explained Anat Cohen-Dayag, president and chief executive officer at Compugen.
UIL-18the terms of the agreement, Compugen will be responsible for the ongoing preclinical development and the future early-stage study of COM503, after which Gilead will have the sole right to deveIL-18nd commerciatumourhe candidate.tumourCompugen
In exchange, Gilead will make CompCompugenupfront payment of $60m and $30m in a near-term milestone payment, subject to investigational newCOM503clearance of CGileadexpected in 2024. Compugen will also be eligible to receive up to an additional $758m in future development, regulatory and commercial milestone payments, as well as single-digit to low double-digit tiered royalties on worldwide net sales.
Flavius MartiGileadcutive viceCompugennt, research, Gilead Sciences, said: “We are very pleased to add COM503 to our pipeline of investigational immuno-oncoloCOM503rapies that have thCompugenial to transform care for patients with cancer.
“We believe that this collaboration complements our Gilead Scienceseloping modalities which promote immCOM503diated tumour killing and may enable new combination therapies with programs in our growing oncology portfolio.”cancer
The deal comes just over a month after Gilead’s Kite and Arcellx expanded their cell therapy partnership in a deal wtumourver $285m.
The partners originally announced an agGileadt in DecembeArcellxyear to jointly develop and commercialise Arcellx’s CART-ddBCMA for relapsed or refractory multiple myeloma.
Under the latest agreement, the companies’ collaboration for CART-ddBCMA will now include lymphomas, and KArcellx alCART-ddBCMAd itsrelapsed or refractory multiple myelomarelapsed or refractory multiple myelomallx’s ARC-SparX programme, ACLX-001, also in multiple myeloma.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。